



06-14-04

IFW

Express Mail No.: EV475140563US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Dingivan *et al.* Confirmation No.: 3565
Serial No.: 10/657,006 Group Art Unit: 1614
Filed: September 5, 2003 Examiner: To Be Assigned
For: METHODS OF PREVENTING OR TREATING T CELL
MALIGNANCIES BY
ADMINISTERING CD2
ANTAGONISTS Attorney Docket No.: 10271-116-999

REQUEST FOR CORRECTION OF FILING RECEIPT

Office of Initial Patent Examination

Filing Receipt Corrections

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

Enclosed is the original Filing Receipt and a copy with handwritten corrections in red for the above-identified non-provisional application. Please correct the title to read as follows: "METHODS OF PREVENTING OR TREATING T CELL MALIGNANCIES BY ADMINISTERING CD2 ANTAGONISTS".

Applicant respectfully requests that the United States Patent and Trademark Office correct its records and issue a corrected Filing Receipt in connection with the above-identified non-provisional patent application.

It is estimated that no fee is required for correction of the Filing Receipt. However, should the Patent Office determine otherwise, please charge the necessary fee to Jones Day Deposit Account No. 503013. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: June 11, 2004

Margaret Brivanlou 40,922
Margaret ~~B~~ Brivanlou (Reg. No.)

By: Lynda Q. Nguyen 54,338
Lynda Q. Nguyen (Reg. No.)
JONES DAY
222 East 41st Street
New York, New York 10017-6702
(212) 790-6424



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/657,006	09/05/2003	1614	2788	10271-116-999	6	43	13

CONFIRMATION NO. 3565

20583
 JONES DAY
 222 EAST 41ST STREET
 NEW YORK, NY 10017

FILING RECEIPT



OC000000011728540

Date Mailed: 01/21/2004


Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).**

Applicant(s)

Christine Dingivan, Germantown, MD; ✓
 Thomas Waldmann, Silver Spring, MD; ✓

Domestic Priority data as claimed by applicant

This appln claims benefit of 60/409,024 09/05/2002
 and claims benefit of 60/410,385 09/12/2002



Foreign Applications

If Required, Foreign Filing License Granted: 01/21/2004

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

Title

Methods of preventing or treating cell malignancies by administering CD2 antagonists

Preliminary Class

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/657,006	09/05/2003	1614	2788	10271-116-999	6	43	13

20583
JONES DAY
222 EAST 41ST STREET
NEW YORK, NY 10017

CONFIRMATION NO. 3565

FILING RECEIPT



OC000000011728540

Date Mailed: 01/21/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Christine Dingivan, Germantown, MD;
Thomas Waldmann, Silver Spring, MD;

Domestic Priority data as claimed by applicant

This appln claims benefit of 60/409,024 09/05/2002
and claims benefit of 60/410,385 09/12/2002

Foreign Applications

If Required, Foreign Filing License Granted: 01/21/2004

Projected Publication Date: To Be Determined - pending completion of Missing Parts


Non-Publication Request: No

Early Publication Request: No

Title

Methods of preventing or treating ^Tcell malignancies by administering CD2 antagonists

Preliminary Class



**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).